Molecular Templates Company Overview
About Molecular Templates
Molecular Templates (NASDAQ:MTEM) specializes in the discovery and development of next-generation immunotoxins for the treatment of cancer and other serious diseases. Their innovative platform technology, Engineered Toxin Bodies (ETB), is designed to create novel therapeutics that target a variety of cancers. Focused on addressing the limitations of current treatments, Molecular Templates is dedicated to advancing a diverse pipeline of ETB candidates through clinical trials with the goal of improving patient outcomes. Their projects include collaborations with larger pharmaceutical companies to harness this technology in creating more effective and less toxic cancer therapies. With a commitment to innovation and a passion for enhancing patient care, Molecular Templates aims to lead the way in the development of novel oncology treatments.
Snapshot
Operations
Products and/or services of Molecular Templates
- MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin's lymphoma treatment.
- MT-6402, a PD-L1 targeted engineered toxin with potential uses in various carcinoma treatments.
- TAK-169, designed to target CD38 for multiple myeloma therapy.
- MT-5111, a HER2-targeted engineered toxin body for treating HER2-positive cancers.
- MT-0169, focused on targeting CTLA-4 for potential immunotherapy enhancements.
- Partnership programs with Takeda Pharmaceutical Company, leveraging engineered toxin bodies for oncology therapeutics.
Molecular Templates executive team
- Dr. Eric E. Poma Ph.D.Interim CFO, Treasurer, Principal Acc. Officer, CEO, Chief Scientific Officer & Director
- Ms. Kristen Quigley B.A.Chief Operating Officer
- Dr. Grace Kim Ph.D.Chief Strategy Officer & Head of IR
- Dr. Michelle Iwamoto-Fan J.D., Ph.D.Senior Vice President & General Counsel
- Dr. Joseph Phillips Ph.D.Senior VP & Head of CMC Development
- Dr. Chris Moore Ph.D.Senior VP and Head of Preclinical Development & Translational Medicine